[1] |
ELYASI S,KHALILI H,DASHTI-KHAVIDAKI S,et al.Vancomycin-induced nephrotoxicity:mechanism,incidence,risk factors and special populations. A literature review[J]. Eur J Clin Pharmacol,2012,68(9):1243-1255.
|
[2] |
LIU C,BAYER A,COSGROVE S E,et al.Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis,2011,52(3):285-292.
|
[3] |
万古霉素临床应用中国专家共识(2011版)[J]. 中国新药与临床杂志,2011,30(8):561-573.
|
[4] |
MARIA A C,EVELINA T,ELISABETTA G,et al.Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections:systematic review and meta-analysis[J]. J Antimicrob Chemother,2012,67:17-24.
|
[5] |
FRYMOYER A,HERSH A L,BENET L Z,et al.Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate[J]. Pediatr Infect Dis J,2009,28(5):398-402.
|
[6] |
BLACK D.Special report:recommendations for vancomycin serum concentration monitoring in adults[J]. Drug Therapy Topics,2005,34(12):55-60.
|
[7] |
VAN HAL S J,PATERSON D L,LODISE T P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter[J]. Antimicrob Agents Chemother,2013,57(2):734-744.
|
[8] |
IWAMOTO T,KAGAWA Y,KOJIMA M.Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin[J]. Biol Pharm Bull,2003,26(6):876-879.
|
[9] |
VÁZQUEZ M,FAGIOLINO P,BORONAT A,et al. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock[J]. Int J Clin Pharmacol Ther,2008,46(3):140-145.
|
[10] |
RYBAK M,LOMAESTRO B,ROTSCHAFER J C,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J]. Am J Health Syst Pharm,2009,66(1):82-98.
|
[11] |
张宏文,王蔚青,刘云,等. 万古霉素血药浓度监测回顾性分析[J]. 药学与临床研究,2009,17(3):257-259.
|
[12] |
KÖNIG K,KOBOLD U,FINK G,et al. Quantification of vancomycin in human serum by LC-MS/MS[J]. Clin Chem Lab Med,2013,51(9):1761-1769.
|
[13] |
SHIRAISHI Y,OKAJIMA M,SAI Y,et al.Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration:screening experiments for linezolid,teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin[J]. Anaesth Intensive Care,2012,40(3):442-449.
|
[14] |
OYAERT M,PEERSMAN N,KIEFFER D,et al.Novel LC-MS/MS method for plasma vancomycin:comparison with immunoassays and clinical impact[J]. Clin Chim Acta,2015,441:63-70.
|
[15] |
JAVORSKA L,KRCMOVA L K,SOLICHOVA D,et al.Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography-a review[J]. J Sep Sci,2016,39(1):6-20.
|
[16] |
TÁCIO DE M L,KARINE S S,JOSÉ CARLOS S G,et al. A rapid and simple HPLC method for therapeutic monitoring of vancomycin[J]. J Chromatograph Sci,2018,56(2):115-121.
|
[17] |
林玉仙,苏煌财. 高效液相色谱法测定万古霉素的血药浓度[J]. 中国医院药学杂志,2009,29(8):637-639.
|
[18] |
李洪亮,乔静,曹玫,等. 6种不同沉淀试剂对万古霉素去甲万古霉素血药浓度测定影响的比较[J]. 山西医药杂志(下半月版),2009,38(24):1154-1155.
|